- If you are trying to figure out whether Medpace Holdings at around US$450 per share is still good value, you are not alone. This article is written with that question front and center.
- The stock has had a mixed run recently, with a 4.3% decline over the last 7 days, a 5.2% gain over 30 days, a 21.1% decline year to date, yet a 38.6% return over 1 year and a 156.4% return over 3 years.
- These moves have kept Medpace on many investors' watchlists, with attention on how its contract research business fits into broader healthcare and biotech trends and how that is reflected in its share price. Recent commentary has focused on its role as a clinical research partner and how demand for outsourced clinical trials could influence sentiment around the stock.
- On Simply Wall St's valuation checks, Medpace scores 4 out of 6 for being assessed as undervalued. This sets up a closer look at how different valuation methods line up for this company and hints at a more holistic way to think about valuation that we will come back to at the end.
Approach 1: Medpace Holdings Discounted Cash Flow (DCF) Analysis
A Discounted Cash Flow, or DCF, model takes projected future cash flows and discounts them back to today, giving an estimate of what the business might be worth in present value terms.
For Medpace Holdings, Simply Wall St uses a 2 Stage Free Cash Flow to Equity model based on cash flow projections. The latest twelve month free cash flow is about $672.7 million. Analysts provide detailed forecasts for the coming years. Beyond that point, the cash flows are extrapolated by Simply Wall St, with projected free cash flow of $829.9 million in 2030. All of these cash flows are in US$.
Combining those discounted projections, the DCF model points to an estimated intrinsic value of about $575.79 per share, compared with the current share price of around $450. On this basis, the model indicates that Medpace is approximately 21.8% undervalued relative to its DCF estimate.
Result: UNDERVALUED
Our Discounted Cash Flow (DCF) analysis suggests Medpace Holdings is undervalued by 21.8%. Track this in your watchlist or portfolio, or discover 48 more high quality undervalued stocks.
Approach 2: Medpace Holdings Price vs Earnings
For a profitable business like Medpace Holdings, the P/E ratio is a straightforward way to think about what you are paying for each dollar of current earnings. It is also widely used across the Life Sciences industry, which makes comparisons easier for you as an investor.
What counts as a “normal” or “fair” P/E depends on how the market views a company’s earnings growth potential and risks. Higher expected growth or lower perceived risk can justify a higher P/E, while slower growth or higher risk usually points to a lower multiple.
Medpace currently trades on a P/E of 28.34x. That sits below the Life Sciences industry average of about 31.63x and below the peer average of 48.44x. Simply Wall St also calculates a proprietary “Fair Ratio” of 23.02x for Medpace, which is the P/E level it estimates would be reasonable given factors such as the company’s earnings growth profile, profit margins, industry, market capitalization and risk characteristics.
This Fair Ratio can be more tailored than a simple peer or industry comparison because it blends these company specific factors into one number. Comparing 28.34x with the Fair Ratio of 23.02x suggests the stock trades above that tailored estimate of fair value.
Result: OVERVALUED
P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.
Upgrade Your Decision Making: Choose your Medpace Holdings Narrative
Earlier we mentioned that there is an even better way to understand valuation. Narratives on Simply Wall St let you attach your own story about Medpace Holdings to the numbers by linking what you think will happen to its revenue, earnings and margins into a financial forecast. That forecast is then turned into a Fair Value, which you can compare to the current share price to help you decide whether you see the stock as attractive or stretched. All of this is done inside an easy Community tool that updates automatically when new information such as news or earnings arrives. One investor might lean toward the higher US$582 fair value and growth assumptions, while another leans toward the lower US$352 view, giving you a clear sense of where your expectations sit on that spectrum.
For Medpace Holdings however we will make it really easy for you with previews of two leading Medpace Holdings Narratives:
These sit on opposite sides of the debate, so you can see which one is closer to how you view the business and the current share price around US$450.41.
Fair value in this bullish narrative: US$582.00 per share
Implied discount to that fair value at the last close: about 22.6% undervalued
Revenue growth assumption in the model: 13.89% per year
- Backlog conversion, efficiency and technology investment are at the center of the story, with analysts modeling stronger margins of about 17.94% and a higher future P/E of roughly 29.35x.
- Analysts in this camp see Medpace as highly efficient per employee and closely tied to biopharma clients where clinical trial activity and funding conditions are framed as supportive for higher fair value estimates.
- Recent work has lifted the implied fair value from US$510.00 to US$582.00, with the higher target linked to execution quality, exposure to biotech programs like the Zelluna partnership, and an updated view on long term earnings power.
Fair value in this bearish narrative: US$352.16 per share
Implied premium to that fair value at the last close: about 27.9% overvalued
Revenue growth assumption in the model: 11.71% per year
- This view leans on concerns that decelerating healthcare utilization could make it harder to support current multiples, even as one key analyst price target has been edged up to US$660 from US$655.
- Analysts here focus on the risk that slower utilization growth, rising costs and execution hurdles around future guidance could pressure the P/E they are willing to use. This feeds into a lower intrinsic value of about US$352.16 and a future P/E of roughly 16.54x.
- While the underlying model keeps revenue growth and profit margins around 11.71% and 17.82% respectively, the main takeaway is that any sign of slower demand or tighter healthcare budgets could put more weight on this lower fair value scenario.
Putting those side by side gives you a clear range, from roughly US$352.16 on the cautious end to about US$582.00 on the optimistic end, with the current share price of US$450.41 sitting between them. Your own view on Medpace will probably lean toward one of these narratives, or somewhere in between, depending on how confident you are about future trial activity, margins and the multiples investors are prepared to pay for those earnings.
Once you have a sense of which story fits you best, it can be helpful to read the full versions, compare the assumptions against your own, and see how other investors in the Community are framing the same set of numbers.
Do you think there's more to the story for Medpace Holdings? Head over to our Community to see what others are saying!
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com